期刊
DALTON TRANSACTIONS
卷 49, 期 36, 页码 12865-12878出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0dt02069a
关键词
-
资金
- VIT
- Department of Science and Technology, Government of India through the DST-EMR project [EMR/2017/000816]
Due to the side effects of marketed cancer drugs, we designed a series of ruthenium-based fluorescent anticancer drugs, which was demonstrated to be target specific, highly cytoselective, lipophilic, water soluble, hypoxia efficient and glutathione resistant. Herein, we developed novel ruthenium(II)-p-cymene-2-aryl-imidazophenanthroline scaffolds as effective DNA-targeting agents. Specifically, the 2-aryl substituted imidazophenanthroline ligands make the Ru(II) complex a decent DNA intercalator by affording planarity. Among the four Ru(II) complexes (RuL1-RuL4), [(eta(6)-p-cymene)(RuCl)-Cl-II{K-2-N,N-(2-(naphthalene-1yl)-1H-imidazo[4,5-f][1,10]phenanthroline)}]PF6 (RuL4) exhibited the best cytoselectivity in two cancer cell lines (Cato-2 and HeLa), and [(eta(6)-p-Cymene)(RuCl)-Cl-II{K-2-N,N-(2-(anthracen-9-yl-1H-imidazo[4,5-f][1,10]phenanthroline)}]PF6 (RuL1) was established as a potent HeLa cell imaging probe.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据